Find Out What

Can Mean for Your Patients1-3

Mozobil + granulocyte-colony stimulating factor (G-CSF) has been shown to improve mobilization compared to G-CSF alone in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).

Get the Details

About Mozobil

Mozobil is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with NHL and MM.1

Mozobil is a first in class CXCR4 receptor antagonist.1

more about mozobil

Dosing and Administration

Begin treatment with Mozobil after the patient has received G-CSF once daily for 4 days. Administer Mozobil approximately 11 hours before initiation of each apheresis while continuing daily G-CSF administration. Mozobil administration can be up to 4 consecutive days.1

More about dosing and administration

Sanofi Genzyme Is Committed to Helping Patients

The CareASSIST Patient Support Program by Sanofi Genzyme is dedicated in providing resources and support for your eligible patients.

  • Access and Reimbursement: Assistance navigating the insurance process, including benefits investigations, claims assistance, and information about prior authorizations and appeals.
  • Financial Assistance: Eligible patients may qualify to receive their prescribed medications at no cost.
  • Resource Support: Information on independent support services for patients and caregivers, as well as product ordering and replacement information.

CareASSIST Patient Support Program

REFERENCES:

  1. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation; 2019.
  2. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
  3. DiPersio JF, Stadtmauer EA, Nademanee A, et al; for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.